BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35471977)

  • 1. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.
    Yuan M; Guo XL; Chen JH; He Y; Liu ZQ; Zhang HP; Ren J; Xu Q
    Neoplasma; 2022 Jul; 69(4):807-819. PubMed ID: 35471977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer.
    Hosseinzadeh S; Imani M; Pourfarzi F; Jafari N; AbedianKenari S; Safarzadeh E
    Med Oncol; 2024 Apr; 41(5):110. PubMed ID: 38592576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
    Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
    Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manganese facilitated cGAS-STING-IFNI pathway activation induced by ionizing radiation in glioma cells.
    He Y; Yang Y; Huang W; Yang S; Xue X; Zhu K; Tan H; Sun T; Yang W
    Int J Radiat Biol; 2023; 99(12):1890-1907. PubMed ID: 37406172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
    Xu P; Wang H; Pan H; Chen J; Deng C
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer.
    Han D; Zhang J; Bao Y; Liu L; Wang P; Qian D
    Cell Death Discov; 2022 Nov; 8(1):468. PubMed ID: 36443299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma.
    Jiang X; Li Y; Zhang N; Gao Y; Han L; Li S; Li J; Liu X; Gong Y; Xie C
    Cell Biosci; 2021 Apr; 11(1):74. PubMed ID: 33858512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment.
    Li J; Cao P; Chen Y; Wang J; Sun X; Chen R; Wang G; Hou J
    Exp Cell Res; 2022 Aug; 417(1):113197. PubMed ID: 35568074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 11. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
    Yang KS; Xu CQ; Lv J
    Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
    Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
    Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer.
    Zheng W; Sun G; Li Z; Wu F; Sun G; Cao H; Zhou J; Ma Y
    Front Surg; 2022; 9():895982. PubMed ID: 35495754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity.
    Anghelina D; Lam E; Falck-Pedersen E
    J Virol; 2016 Jul; 90(13):5915-27. PubMed ID: 27076643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.
    Chen J; Hai Y; Hu Q; Chen C; Jiang X; Gao Y
    Pharm Res; 2023 Mar; 40(3):689-699. PubMed ID: 36539669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer.
    Luo Z; Xu J; Xu D; Xu J; Zhou R; Deng K; Chen Z; Zou F; Yao L; Hu Y
    Immun Inflamm Dis; 2023 Jul; 11(7):e851. PubMed ID: 37506147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING and cGAS gene expressions were downregulated among HIV-1-infected persons after antiretroviral therapy.
    de Lima LLP; de Oliveira AQT; Moura TCF; da Silva Graça Amoras E; Lima SS; da Silva ANMR; Queiroz MAF; Cayres-Vallinoto IMV; Ishak R; Vallinoto ACR
    Virol J; 2021 Apr; 18(1):78. PubMed ID: 33858455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.